Storia della carriera di Albert Paszek
Precedenti posizioni note di Albert Paszek
Società | Posizione | Inizio | Fine |
---|---|---|---|
MUSTANG BIO, INC. | Direttore Tecnico/Scientifico/R&S | 01/10/2019 | 10/10/2023 |
ALEXION PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/02/2016 | 01/08/2017 |
SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - | - |
ABEONA THERAPEUTICS INC. | Corporate Officer/Principal | - | - |
Formazione di Albert Paszek
University of Minnesota | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Settori
Health Technology | 5 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
MUSTANG BIO, INC. | Health Technology |
ABEONA THERAPEUTICS INC. | Health Technology |
Aziende private | 2 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- Albert Paszek
- Esperienza